Amgen To Acquire Privately Held Teneobio For $900 Million In Cash With Future Contingent Milestone Payments
The Pharma Data
JULY 27, 2021
“Over the last five years, Teneobio developed leading-edge expertise in efficiently engineering differentiated multispecific and bispecific therapeutics for numerous indications with potentially better safety, efficacy and pharmacokinetic profiles than the first generation of T-cell engagers. chief executive officer of Teneobio.
52 
Let's personalize your content